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during veno-venous extracorporeal membrane 
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A retrospective analysis of the ELSO database
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Abstract 
Background: Single- (SL) and double-lumen (DL) catheters are used in clinical practice for veno-venous extracorpor-
eal membrane oxygenation (V-V ECMO) therapy. However, information is lacking regarding the effects of the cannula-
tion on neurological complications.
Methods: A retrospective observational study based on data from the Extracorporeal Life Support Organization 
(ELSO) registry. All adult patients included in the ELSO registry from 2011 to 2018 submitted to a single run of V-V 
ECMO were analyzed. Propensity score (PS) inverse probability of treatment weighting estimation for multiple treat-
ments was used. The average treatment effect (ATE) was chosen as the causal effect estimate of outcome. The aim of 
the study was to evaluate differences in the occurrence and the type of neurological complications in adult patients 
undergoing V-V ECMO when treated with SL or DL cannulas.
Results: From a population of 6834 patients, the weighted propensity score matching included 6245 patients 
(i.e., 91% of the total cohort; 4175 with SL and 20,270 with DL cannulation). The proportion of patients with at least 
one neurological complication was similar in the SL (306, 7.2%) and DL (189, 7.7%; odds ratio 1.10 [95% confidence 
intervals 0.91–1.32]; p = 0.33). After weighted propensity score, the ATE for the occurrence of least one neurological 
complication was 0.005 (95% CI − 0.009 to 0.018; p = 0.50). Also, the occurrence of specific neurological complica-
tions, including intracerebral hemorrhage, acute ischemic stroke, seizures or brain death, was similar between groups. 
Overall mortality was similar between patients with neurological complications in the two groups.
Conclusions: In this large registry, the occurrence of neurological complications was not related to the type of can-
nulation in patients undergoing V-V ECMO.
Keywords: Extracorporeal membrane oxygenation, V-V ECMO, Neurological complications, Respiratory failure, 
Cannulation, Seizure, Propensity score
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Introduction
Veno-venous (V-V) extracorporeal membrane oxygena-
tion (ECMO) can be lifesaving in severe respiratory 
failure [1]. According to Extracorporeal Life Support 
Organization (ELSO), the reported survival rate is 
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66%, when considering more than 15,000 treated adult 
patients [2]. In particular, young patients with severe 
respiratory failure, who are typically treated during the 
influenza epidemics, may demonstrate even major ben-
efits when V-V ECMO is implemented [3, 4].
However, the use of V-V ECMO is not without risks 
and neurologic complications have been reported, 
although their incidence is lower than in patients 
undergoing veno-arterial (V-A) ECMO [5–7]. Accord-
ing to a recent retrospective cohort study from the 
Extracorporeal Life Support Organization (ELSO) Reg-
istry including 4,988 patients treated with V-V ECMO, 
356 (7%) of them suffered from neurological complica-
tions, in particular intra-cranial hemorrhage (42.5%), 
stroke (19.9%), seizures (14.1%) and brain death (23.5%) 
[8]. The current mechanistic understanding of neuro-
logic injury during V-V ECMO is limited. Several puta-
tive risk factors have been proposed, including acute 
renal failure and a rapid  PaCO2 decrease at the time of 
ECMO cannulation [5]. Cerebral micro-emboli have 
also been detected in patients undergoing both V-V and 
V-A ECMO and may play a role in the cerebrovascu-
lar injury [9]. Another potential contributing factor to 
neurologic injury during V-V ECMO is cerebral venous 
congestion, which may be caused by large cannulas in 
the internal jugular veins or venous thrombosis [10, 11, 
13]. This phenomenon has been also confirmed in an 
animal ECMO models [12].
V-V ECMO is currently performed using either sin-
gle- (SL) or dual-lumen (DL) cannulas. DL V-V ECMO 
cannulas have several potential advantages, including 
single vessel cannulation, facilitation of ambulation and 
less recirculation [14, 15]. However, DL V-V ECMO 
cannulas are also characterized by larger sizes (i.e. 
27–31 French in most of cases) than SL, which might 
predispose patients to cerebral venous congestion [15]. 
A previous single-center observational study conducted 
in patients undergoing V-V ECMO with DL cannula-
tion reported a rate of intracranial hemorrhage of 7%; 
only 20% of these patients survived to hospital dis-
charge [16]. In an additional study focusing on a pedi-
atric population on V-V ECMO, no differences were 
observed in the total complications and survival rate 
between SL and DL cannulations [17]. Interestingly, 
there was a nonsignificant trend towards a lower rate of 
neurological complications in the SL group.
Taking all these data into account, we hypothesize 
that the use of DL in V-V ECMO patients may be asso-
ciated with a higher rate of neurologic injury. For these 
reasons, we evaluated the occurrence and the type of 
neurologic complications in a large cohort of adult 
patients on V-V ECMO, according to the SL or DL 
cannulation.
Methods
Study design, setting and participants
This is a retrospective study including adult patients 
undergoing V-V ECMO from 2011 to 2017. All data were 
extracted from the ELSO database (until 2018). Patients 
supported with V-A ECMO, those supported with VV-
ECMO for cardiac indications, and those supported with 
multiple ECMO runs were excluded. Patients less than 
18  years of age were also excluded. The ELSO registry 
collects data on all ECMO cases from approximately 800 
centers around the world since 1989. Data are collected 
using a standardized data collection form. Data user 
agreement between ELSO and member centers allows 
the use of deidentified datasets for research without need 
for further regulatory approval.
Collected variables
For all patients, we collected the following variables from 
the ELSO database: age, gender, weight, cannulation 
type (SL vs. DL), total ECMO hours, pre-ECMO arrest, 
fraction of inspired oxygen  (FiO2) before ECMO, peak 
inspiratory pressure before ECMO, positive end expira-
tory pressure before ECMO, pH before ECMO,  PaCO2 
before ECMO,  PaO2 before ECMO, serum bicarbonate 
level before ECMO, intubation hours before ECMO, and 
pump flow at 4 h and 24 h after ECMO initiation.
Study end point
The primary end point of the study was to evaluate the 
occurrence of neurological complications in the SL and 
DL group. ELSO registry categorizes “neurologic injury” 
as intracranial hemorrhage (ICH), acute ischemic stroke 
(AIS), seizures (either clinical and/or on electroencepha-
lography, EEG) and brain death (BD) that occur during 
the ECMO run. All the cases are also confirmed, at least 
for ICH and AIS, by a neurologist and serial CT scans. 
Additional data on severity, site, timing and functional 
long-term neurologic recovery were not available. Sec-
ondary outcomes included the type of neurological com-
plications (i.e. hemorrhagic stroke, ischemic stroke and 
seizure) in the two groups.
Statistical analysis
Propensity score (PS) inverse probability of treatment 
weighting estimation for multiple treatments was used. 
The balance was tested either graphically or utilizing 
balance tables. Graphical estimation used standardized 
effect plots and quantile–quantile plots, which provide 
an immediate visual evaluation of balance quality. In each 
model, absolute standardized mean differences (ASMD) 
were calculated using a cutoff of less than 0.10 for bias 
statistics. The average treatment effect (ATE) was cho-
sen as the causal effect estimate of each outcome. It was 
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defined as the ratio of the incidence of the outcome in 
the entire population undergoing one treatment over the 
impact of the outcome of the whole population under 
another treatment [18].
Inverse Probability of Treatment Weighting (IPTW) 
was used to correct for imbalances between groups on 
pre-treatment covariates so that the distribution of the 
pre-treatment characteristics would be similar across 
all the groups. A machine learning technique, general-
ized boosted model (GBM), was used to estimate the 
PS weights. GBM estimation captures complex relation-
ships between treatment assignment and pre-treatment 
variables without over-fitting data, and GBM can be 
fine-tuned to find the best balance among groups. IPTW 
is one technique for reducing the bias due to observed 
variables. It relies on two key conditions for obtaining 
unbiased estimates 1: (1) No unknown or unmeasured 
confounders assumption or exchangeability and (2) Suf-
ficient overlap or positivity: 0 < Pr (Ti = t|X) < 1, for all 
X and t, where Ti is the random treatment assignment 
variable, Pr is probability, X is the vector of observed 
treatment covariates and t is the treatment. The first 
assumption states that the set of observed variables is 
rich enough to include all variables influencing both 
treatments and outcomes. The second condition states 
that each patient has a non-zero probability of receiv-
ing each treatment. Both assumptions were met in our 
models.
For our outcomes, many simple regression trees were 
generated starting from a single regression tree and add-
ing another tree at each new iteration to create an overall 
piecewise constant function. This iterative fitting algo-
rithm was chosen so as to provide the best fit to the resid-
uals of the model from the previous iteration and because 
it offers the greatest increase to the log likelihood for the 
data. Indeed, each iteration increases the likelihood mak-
ing the model sufficiently flexible to perfectly fit data. 
To avoid data overfitting, GBM selects an intermediate 
iteration (or number of trees) for the final model so as 
to “minimize an external criterion such as out-of-sam-
ple prediction error or—in the case of propensity score 
estimation—imbalance on the pre-treatment covariates 
across the treatment and control groups. Therefore, the 
key is to use GBM iteratively with the optimal iteration 
(number of trees) for estimating the PS and minimizing a 
“stopping rule” criterion based on the difference between 
the weighted distributions of the pre-treatment vari-
ables in the two treatment conditions. In practice, differ-
ent stopping rules have been used to select the optimal 
iteration of GBM for use in estimating propensity score 
weights: maximum or minimum absolute standard-
ized bias (SB, also referred to as the absolute standard-
ized mean difference) or the Kolmogorov–Smirnov (KS) 
statistic, each of which compares the means or the dis-
tributions of the covariates between treatment groups. 
Since the balance was nearly invariant with the stop-
ping rule, we used the max Kolmogorov–Smirnov (KS) 
statistic.
For 2 groups the KS is:
where EDF is the empirical distribution function for the 
treatment and control samples and k is the covariate. 
Causal effects can be estimated through two different 
summaries: average treatment effect (ATE) and average 
treatment effect between treatments (ATT). The ATE of 
treatment “ti” versus treatment “tj” is the comparison of 
mean outcome had the entire population been observed 
under treatment “ti” versus had the entire population 
been observed under treatment “ti”. The ATT of “ti” ver-
sus “tj” is the comparison of the mean “ti” patient out-
come with the mean outcome they would have had if 
they had instead been treated by “tj” treatment. The cas-
ual effect was estimated by ATE which takes into account 
summary statistics of the effects across populations of 
interest.
R software v. 3.6.1 (R Foundation for Statistical Com-
puting, Vienna, Austria) and the TWANG and SURVEY 
packages were used for analysis.
Results
Study population
A total of 6,834 patients met the inclusion criteria; of 
those, 4367 (63.9%) had SL cannulation and 2467 (36.1%) 
had DL cannulation. Table  1 shows characteristics of 
the study population by cannulation type. Interestingly, 
patients who underwent SL cannulation were older, less 
likely female, had fewer total ECMO hours and lower 
body weight. Despite similar ventilatory parameters prior 
to ECMO, peak inspiratory pressures were slightly lower 
in the SL than in the DL group. Also, mean  PaCO2,  PaO2, 
and bicarbonate levels were significantly lower and pump 
flows higher in SL group than others.
After propensity score, a total of 6245 patients (i.e. 91% 
of the total cohort; 4175 with SL and 20,270 with DL can-
nulation) were included for the outcome analysis. The 
maximum pairwise ASMD was 0.10 for all selected vari-
ables (Additional file 1: S1–3).
Types of neurologic injury and outcome
Considering the entire cohort, 306 (7.2%) patients in 
the SL group had at least one neurological injury: ICH 
in 161 patients (3.8%), AIS in 73 patients (1.7%), sei-
zures in 52 patients (1.2%; 44/52 clinically determined) 
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hundred-eighty-nine (7.7%; OR 1.10 [0.91–1.32]; p = 0.33 
vs. SL group) patients in the DL group had at least one 
neurological injury: ICH in 99 patients (4.0%; OR 1.09 
[0.84–1.41]; p = 0.51 vs. SL group), AIS in 42 patients 
(1.7%; OR 1.01 [0.69–1.49]; p = 0.92 vs. SL group), sei-
zures in 33 patients (1.3%; 27/33 clinically determined—
OR 1.10 [0.72–1.67]; p = 0.66 vs. SL group) and BD in 
44 patients (1.8%; OR 1.02 [0.71–1.48]; p = 0.92 vs. SL 
group) (Table 2; Fig. 1).
When comparing DL to SL configuration, the ATE for 
the occurrence of least one neurological complication 
was 0.005 (95% CI − 0.009 to 0.018; p = 0.50), for ICH 
was 0.003 (95% CI − 0.007 to 0.013; p = 0.50), for AIS was 
0.001 (95% CI − 0.007 to 0.007; p = 0.95), for seizures was 
0.001 (95% CI − 0.005 to 0.006; p = 0.81) and for BD was 
− 0.002 (− 0.008 to 0.005; p = 0.63).
The overall survival rate was lower in the DL than the 
SL group (64.0% vs. 60.8%, p = 0.002—Table  3—ATE: 
0.033 [0.008–0.059]; p = 0.01). However, survival was 
similar among DL and SL among all the subgroups of 
neurological injuries (Table  3). When comparing DL to 
SL configuration, the ATE for survival in patients with at 
least one neurological complication was − 0.046 (− 0.127 
to 0.035; p = 0.27).
Discussion
In this study based on a large international registry, we 
observed that DL V-V ECMO cannulation was associated 
with a similar occurrence of neurological complications 
than SL cannulation. Also, mortality was higher in the SL 
group, but similar across different types of neurological 
injury, regardless of the type of cannulation.
DL cannulation has several potential advantages 
over traditional cannulation, including easier ambula-
tion and reduced recirculation. However, it remains 
unclear whether this approach would increase the risk 
of specific complications in such patients. We analyzed 
a large registry including ECMO centers which report 
routinely their data; also, using a matching method, we 
compared similar populations of patients undergoing 
V-V ECMO and receiving two different type of can-
nulation. In this study, DL cannulation was associated 
with a similar incidence of neurological complications 
than DL. Few data are available on the occurrence of 
seizures in adult patients undergoing V-V ECMO. In 
a recent study including 139 patients undergoing both 
Table 1 Main patients characteristics, before weighing using a 
propensity score
Data are presented as count (%) or median (IQRs)
DL double lumen cannula, SL single-lumen cannula, ECMO extracorporeal 
membrane oxygenation, PEEP positive end expiratory pressure, PIP peak 
inspiratory pressure
Variable DL SL p value
N = 2467 N = 4367
Age (years) 46 (32–58) 48 (35–60)  < 0.0001
Male gender [n (%)] 1386 (56.5) 2612 (62.0)  < 0.0001
Weight (kg) 83 (70–102) 80 (68–100) 0.0001
Total ECMO hours 191 (97–362) 189 (96–336) 0.058
Pre-ECMO arrest [n (%)] 165 (6.7) 294 (6.7) 0.984
FiO2 prior to ECMO (%) 100 (100–100) 100 (100–100) 0.608
PIP prior to ECMO  (cmH2O) 35 (30–40) 34 (30–38)  < 0.0001
PEEP prior to ECMO 
 (cmH2O)
13 (10, 16) 14 (10, 16) 0.367
pH prior to ECMO 7.24 (7.14–7.33) 7.24 (7.15–7.34) 0.152
PaCO2 prior to ECMO 
(mmHg)
57 (43–75) 52 (37–69)  < 0.0001
PaO2 prior to ECMO 
(mmHg)
59 (45–75) 56 (41, 72)  < 0.0001
HCO3 prior to ECMO 
(mEq/L)
25 (21–31) 24 (20–29)  < 0.0001
Intubation hours prior to 
ECMO
45 (13–131) 41 (15–120) 0.166
Pump flow at 4 h (L/min) 4.0 (3.4–4.5) 4.0 (3.4–4.8)  < 0.01
Pump flow at 24 h (L/min) 4.0 (3.4–4.6) 4.1 (3.4–4.8)  < 0.01
Alive at hospital discharge 
[n (%)]
1580 (64.0) 2595 (60.8) 0.002
Table 2 Neurologic complications according to the cannulation strategy, before weighing using a propensity score
DL double lumen cannula, SL single-lumen cannula, OR odds ratio, CI confidence intervals, ICH intracranial hemorrhage, AIS acute ischemic stroke, CNS central nervous 
system
Variable DL SL OR Lower 95% CI Upper 95% CI p value
N = 2467 N = 4367
Patients with CNS Compli-
cations
189 (7.7%) 306 (7.2%) 1.10 0.91 1.32 0.33
ICH 99 (4.0%) 161 (3.8%) 1.09 0.84 1.41 0.51
AIS 42 (1.7%) 73 (1.7%) 1.01 0.69 1.49 0.92
Seizures 33 (1.3%) 52 (1.2%) 1.10 0.72 1.67 0.66
Brain death 44 (1.8%) 76 (1.8%) 1.02 0.71 1.48 0.92
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veno-arterial (V-A) and V-V ECMO concomitantly with 
EEG monitoring, Peluso et  al. reported an 8% occur-
rence of seizures or status epilepticus [19], which was 
independent from ECMO configuration. Nevertheless, 
no DL cannulation was used in this cohort. In a large 
registry analysis (N = 4988), Lorusso et al. reported 60 
patients with seizures (1.2%), mostly being clinically 
diagnosed [7]. The use of EEG monitoring has already 
shown to increase the detection of seizures, which are 
mainly non-convulsive in critically ill patients [20]; 
unfortunately, in many ECMO centers continuous 
EEG monitoring is not routinely implemented or not 
available, and the real occurrence of seizures might 
have been largely underestimated. Also, as some sei-
zures were “clinically determined”, it remains unknown 
whether they were convulsions or other forms of 
abnormal movements, which might occur in criti-
cally ill patients. Moreover, few studies have tried to 
assess the causes of epileptic complications in ECMO 
patients. If in critically ill patients admitted for medical 
causes, sepsis, drug toxicity, metabolic disturbances or 
discontinuation of antiepileptic drugs have been associ-
ated with a higher probability of seizures [21–23], our 
study was unable to assess those factors and suggested 
no additional role for the selection of cannulation on 
the occurrence of such complication.
In this study, the occurrence of other type of neuro-
logical injuries, such as intracranial hemorrhage, acute 
ischemic infarction and brain death, was also similar 
between DL than SL cannulation. A previous analysis of 
a French cohort consisting of 135 consecutive patients 
undergoing V-V ECMO showed that 14.1% had a neuro-
logic injury [5]. The majority of these events were ICH, 
with only a small number of ischemic strokes or dif-
fuse microbleeds. In the present study, with more than 
2000 patients included, the total number of neurological 
events was less than half when compared to that previ-
ously reported [5, 7]. Of course, differences in age, indi-
cations for ECMO, use of anticoagulation, the presence 
of previous neurological diseases and different policies 
to obtain cerebral CT scan might also explain these find-
ings. The pathophysiology of neurologic injury during 
V-V ECMO is complex with many processes potentially 
playing a role. These include frequent changes in  PaO2 
and  PCO2, that can affect cerebral blood flow, forma-
tion of cerebral micro-emboli and venous congestion 
from cannulation of the internal jugular veins. Further-
more abrupt changes in local and systemic blood pres-
sure, ischemia/reperfusion, anticoagulation and venous 
hypertension caused by distal internal vein ligation have 
also been reported to play a contributory role [24, 25]. 
To date, there are few detailed investigations of cer-
ebral blood flow and cerebral venous return in ECMO 
patients. In one study of pediatric ECMO patients, cere-
bral blood flow velocities were below normal ranges [26]; 
the authors of this study concluded that reduced blood 
flow velocities could be due to the decreased cerebral 
metabolic demands associated with sedation, cerebral 
venous congestion, or reduced cardiac function during 
ECMO. Future studies using more precise assessment of 
cerebral blood flow (i.e. cerebral CT-perfusion) in asso-
ciation with additional neuromonitoring are necessary to 
understand the pathophysiology of neurological compli-
cations in ECMO patients and potentially help for their 
prevention.
DL cannulas in adults are large, because both the 
inflow and outflow cannulas must be accommodated 
within a single catheter. This provides the advantage in 
Fig. 1 Occurrences of various neurological injuries in the study 
population, according to the cannulation strategy. DL dual lumen, SL 
single lumen
Table 3 Patient outcomes, according to the cannulation strategy, before weighing using a propensity score
DL double lumen cannula, SL single-lumen cannula, OR odds ratio, CI confidence intervals, CNS central nervous system
Variable DL SL OR Lower 95% CI Upper 95% CI p value
N = 2467 N = 4367
Discharged alive, all 1580 (64.0) 2595 (60.8) 1.13 0.96 1.34 0.002
Discharged alive, ICH 21/99 (21.0%) 35/161 (21.7%) 0.96 0.52 1.78  > 0.99
Discharged alive, AIS 7/42 (16.6%) 24/73 (32.8%) 0.41 0.16 1.03 0.08
Discharged alive, seizures 13/33 (39.4%) 26/52 (50.0%) 0.65 0.28 1.56 0.38
Discharged alive, CNS complications 38/189 (20.1%) 79/306 (25.8%) 0.72 0.46 1.11 0.16
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that only one vein needs to be accessed to provide full 
ECMO support to the patient. However, it is unclear 
whether large cannulas can be safely accommodated in 
the internal jugular veins without affecting cerebral blood 
flow dynamics. Cases of cerebral edema have been pre-
viously reported with internal jugular vein thrombosis, 
particularly when the contralateral internal jugular vein 
is hypoplastic or compromised [27]. In one small study 
of neurosurgical patients who had continuous intrac-
ranial pressure monitoring, cannulation of the right 
internal jugular vein was not associated with increases 
in intracranial pressure [28]. However, a previous case 
report indicated that bilateral cannulation in the internal 
jugular vein should be avoided, since it can increase the 
risk of intracranial hypertension due to impaired venous 
drainage. This could ultimately have repercussions on 
intracranial blood volume and pressure [29]. Recently, 
Sutter et al. [30] published a systematic review on neuro-
logical complication during VA and VV ECMO support, 
and they observed a similar proportion of neurological 
complications than in our study, with a higher incidence 
in patients treated with VA ECMO respect VV ECMO. 
Moreover, they observed a eightfold increased risk for 
AIS if the pre-ECMO lactates were above 10 mmol/L and 
a 18-fold increased risk for ICH in patients with throm-
bocytopenia. These additional factors should be taken 
into consideration for future studies dealing with the 
association of neurological complications and type of 
cannulation in ECMO patients.
Importantly, the findings of this study should be 
approached with caution, since there are several impor-
tant limitations in our analysis. First, a number of cent-
ers use large return cannulas with DL cannulation (i.e. 
25–27 French or greater) [31], so that the risk in terms 
of jugular vein obstruction would be similar in the two 
study groups. Unfortunately, the ELSO database does 
not contain data on cannula size for all patients, so we do 
not know how many patients in the SL group had large 
size return cannulas and could not adjust our analy-
ses accordingly. Secondly, we do not know how many 
patients in each group had bilateral internal jugular vein 
cannulation; it is possible that a significant number of 
patients in both groups had a contralateral central venous 
catheter placed for vasoactive medication infusion or for 
other purposes and this might also contribute to alter the 
cerebral venous return. Thirdly, neurologic events are 
likely to be under-reported in the ELSO database because 
neurologic events during ECMO are often unrecognized 
or not confirmed. Obtaining magnetic resonance imag-
ing scans is not feasible in ECMO patients and many 
patients are not taken for computed tomography scans 
because of the technical difficulties in moving ECMO 
patients or their inherent hemodynamic or respiratory 
instability. Forth, some other factors, including changes 
in  PaCO2 after ECMO implementation, pre-ECMO bili-
rubin levels or the use of renal replacement therapy [32], 
have been associated with a higher risk for neurological 
complications in VV ECMO patients but were not avail-
able in our database. Finally, although reporting data to 
the ELSO database, it remains unknown whether partici-
pating centers had similar practices in managing ECMO 
patients as treatment variability might represent a signifi-
cant confounder for our findings.
Our study also has important strengths. First, it is 
the largest study to examine whether DL ECMO can-
nulation is associated with an increased rate of adverse 
neurologic events. Furthermore, we used data from a 
well-established registry that has quality controls in place 
and represents a worldwide population. Finally, we used a 
propensity matching score to reduce imbalances between 
groups.
Conclusions
Our findings showed that DL cannulation during V-V 
ECMO was not associated with an increased risk of 
neurological complications when compared with SL. 
Despite a higher survival rate in patients treated with 
DL, no differences in survival between the two cannula 
configurations were observed when patients with neu-
rological injury were analyzed. Additional prospective 
studies should be encouraged to compare the effects of 
VV-ECMO cannulation on neurological events.
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